The NS5A Inhibitor GS-5885 Is Safe and Well-Tolerated in Over 1000 Patients Treated in Phase 2 Studies

Gregory T Everson, Eric Lawitz, Alexander J Thompson, Mark S Sulkowski, Yanni Zhu, Diana M Brainard, Laura Mendelson, John G McHutchison, Phil S Pang, Jenny C Yang, Patrick Marcellin, Nezam Afdhal